Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyung-Hun Lee

Showing results (131-140 of 248) with videos related to

Pageof 25
Sort By:
Digestive Diseases and Sciences|November 28, 2013
Colonic mucosal immune activity in irritable bowel syndrome: comparison with healthy controls and patients with ulcerative colitisJi Yong Ahn, Kyung Hun Lee, Chang Hwan Choi, et al.
Breast Cancer Research : BCR|April 19, 2015
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cellsAhrum Min, Seock-Ah Im, Debora Keunyoung Kim, et al.
Cancer Research and Treatment|September 25, 2020
Association of Insulin, Metformin, and Statin with Mortality in Breast Cancer PatientsMihong Choi, Jiyeon Han, Bo Ram Yang, et al.
Lung Cancer (Amsterdam, Netherlands)|September 8, 2006
Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patientsSae-Won Han, Tae-You Kim, Kyung-Hun Lee, et al.
Journal of Breast Cancer|December 30, 2017
Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Palliative Treatment for Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Retrospective AnalysisJin Hyun Park, Seock-Ah Im, Ja Min Byun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2006
Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylationSae-Won Han, Tae-You Kim, Yoon Kyung Jeon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric CancerChan-Young Ock, Keun-Wook Lee, Jin Won Kim, et al.
Molecular Cancer Therapeutics|May 20, 2016
Src as a Therapeutic Target in Biliary Tract CancerAh-Rong Nam, Ji-Won Kim, Ji Eun Park, et al.
International Journal of Cancer|February 6, 2019
Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patientsJi-Yeon Kim, Eunjin Lee, Kyunghee Park, et al.
Cancer Research and Treatment|August 25, 2016
Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in KoreaSeung Hoon Beom, Jisu Oh, Tae-Yong Kim, et al.
Pageof 25

Showing results (131-140 of 248) with videos related to

Sort By:
Pageof 25
Digestive Diseases and Sciences|November 28, 2013
Colonic mucosal immune activity in irritable bowel syndrome: comparison with healthy controls and patients with ulcerative colitisJi Yong Ahn, Kyung Hun Lee, Chang Hwan Choi, et al.
Breast Cancer Research : BCR|April 19, 2015
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cellsAhrum Min, Seock-Ah Im, Debora Keunyoung Kim, et al.
Cancer Research and Treatment|September 25, 2020
Association of Insulin, Metformin, and Statin with Mortality in Breast Cancer PatientsMihong Choi, Jiyeon Han, Bo Ram Yang, et al.
Lung Cancer (Amsterdam, Netherlands)|September 8, 2006
Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patientsSae-Won Han, Tae-You Kim, Kyung-Hun Lee, et al.
Journal of Breast Cancer|December 30, 2017
Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Palliative Treatment for Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Retrospective AnalysisJin Hyun Park, Seock-Ah Im, Ja Min Byun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2006
Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylationSae-Won Han, Tae-You Kim, Yoon Kyung Jeon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric CancerChan-Young Ock, Keun-Wook Lee, Jin Won Kim, et al.
Molecular Cancer Therapeutics|May 20, 2016
Src as a Therapeutic Target in Biliary Tract CancerAh-Rong Nam, Ji-Won Kim, Ji Eun Park, et al.
International Journal of Cancer|February 6, 2019
Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patientsJi-Yeon Kim, Eunjin Lee, Kyunghee Park, et al.
Cancer Research and Treatment|August 25, 2016
Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in KoreaSeung Hoon Beom, Jisu Oh, Tae-Yong Kim, et al.
Pageof 25